Document is current
Any future updates will be listed below
-
Authors
Wiechmann, Tobias http://orcid.org/0000-0003-0001-3613
Röh, Simone
Sauer, Susann
Czamara, Darina
Arloth, Janine
Ködel, Maik
Beintner, Madita
Knop, Lisanne
Menke, Andreas
Binder, Elisabeth B.
Provençal, Nadine
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (FKZ 01KR1301B)
European Research Council (281338)
- License Information
-
More Information
Article History
Received: 27 November 2018
Accepted: 9 May 2019
First Online: 23 May 2019
Authors’ information
: Not applicable
: All studies were approved by the local ethics committee of the Medical School of the Ludwig Maximilians University, and all participants gave informed consent.
: Not applicable
: EBB is co-inventor of the European patent application <i>FKBP5</i>: a novel target for antidepressant therapy <i>European Patent# EP</i> 1687443 B1 and receives a research grant from Böhringer Ingelheim to investigate <i>FKBP5</i> as a candidate target in psychiatric disorders. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
